STOCK TITAN

Cytokinetics EVP Malik exercises options for 3,500 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Cytokinetics, Inc. (CYTK) EVP Research & Development Fady Ibraham Malik exercised options for 3,500 shares at a $7.80 exercise price on November 17, 2026, receiving 3,500 common shares; 9,386 options remained after the transaction. He sold 3,300 shares at a weighted average price of $51.73, with reported sales ranging from $51.39 to $52.37, and sold 200 shares at a weighted average price of $52.59, with reported sales ranging from $52.52 to $52.66. The transactions were reported under a Rule 10b5-1 plan.

Insider Malik Fady Ibraham
Role EVP Research & Development
Sold 3,500 shs ($181K)
Approx. gross sale proceeds $181K
Approx. exercise cost $27K
Approx. pre-tax spread $154K
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (Right to Buy) 3,500 $0.00 $0.00
Exercise Common Stock 3,500 $7.80 $27K
Sale Common Stock F1 3,300 $51.73 $171K
Sale Common Stock F2 200 $52.59 $11K
Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 9,386 options (Direct); Common Stock — 153,902 shares (Direct)
Footnotes (2)
  1. F1. The reported transaction involves sale transactions from $51.39 to $52.37 per share. The weighted average price per share was $51.73. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.
  2. F2. The reported transaction involves sale transactions from $52.52 to $52.66 per share. The weighted average price per share was $52.59. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.
Options exercised 3,500 shares November 17, 2026
Exercise price $7.80 per share Options exercised November 17, 2026
Options following transaction 9,386 shares Following the November 17, 2026 transaction
Shares sold 3,300 shares November 17, 2026; weighted average price $51.73 per share
Weighted average sale price $51.73 per share 3,300 shares sold November 17, 2026
Shares sold 200 shares November 17, 2026; weighted average price $52.59 per share
Weighted average sale price $52.59 per share 200 shares sold November 17, 2026
Non-Qualified Stock Option technical
"the exercised Non-Qualified Stock Option"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average price financial
"the weighted average price per share was $51.73"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 regulatory
"the reported transactions were under a Rule 10b5-1 plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CYTK shares did Fady Ibraham Malik sell on November 17, 2026?

He sold 3,300 shares at a weighted average price of $51.73 and 200 shares at a weighted average price of $52.59. The respective reported transaction price ranges were $51.39 to $52.37 and $52.52 to $52.66. The sales were under a Rule 10b5-1 plan.

How many CYTK options did Fady Ibraham Malik exercise, and at what price?

He exercised options for 3,500 shares at a $7.80 exercise price. The option position was reported as 9,386 shares following the transaction, which occurred on November 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Malik Fady Ibraham

(Last)(First)(Middle)
350 OYSTER POINT BLVD

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP Research & Development
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026M3,500A$7.8157,402D
Common Stock11/17/2026S3,300D$51.73(1)154,102D
Common Stock11/17/2026S200D$52.59(2)153,902D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (Right to Buy)$7.811/17/2026M3,50003/27/201802/27/2028Common Stock3,500$09,386D
Explanation of Responses:
1. The reported transaction involves sale transactions from $51.39 to $52.37 per share. The weighted average price per share was $51.73. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.
2. The reported transaction involves sale transactions from $52.52 to $52.66 per share. The weighted average price per share was $52.59. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.
/s/ Jeff Hessekiel, attorney-in-fact for Dr. Malik11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading